Skip to main content

Advertisement

Table 4 SF-12v2 and SIBDQ scores for the maintenance phase sample at acute and maintenance phase visits

From: Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study

   Baseline Week 8 Month 12   Post hoc comparisons (Bonferroni-adjusted P [α/3])
N LS Mean SE LS Mean SE LS Mean SE P Baseline vs. Week 8 Baseline vs. Month 12 Week 8 vs. Month 12
SF-12v2
 Physical functioning 456 46.3 0.46 52.6 0.36 52.6 0.40 1.0000
 Role physical 456 44.5 0.38 51.7 0.29 51.2 0.39 0.8573
 Bodily pain 455 43.7 0.44 54.1 0.27 52.6 0.41
 General health 456 41.2 0.49 51.1 0.38 50.9 0.53 1.0000
 Vitality 456 47.3 0.45 55.7 0.42 56.0 0.51 1.0000
 Social functioning 456 43.1 0.45 51.8 0.34 50.7 0.44 0.0666
 Role emotional 456 41.9 0.47 49.9 0.35 49.8 0.42 1.0000
 Mental health 456 44.5 0.45 53.5 0.39 53.7 0.48 1.0000
 PCS 456 45.0 0.38 52.6 0.27 52.0 0.37 0.3256
 MCS 456 43.6 0.45 52.2 0.36 52.3 0.44 1.0000
SIBDQ
 Bowel symptoms 406 12.8 0.17 18.1 0.13 17.3 0.20
 Systemic symptoms 405 9.1 0.14 11.5 0.11 11.4 0.13 0.6393
 Emotional function 404 13.1 0.21 17.4 0.16 17.0 0.21 0.1070
 Social function 406 9.2 0.16 12.6 0.10 12.2 0.14 *
 Total score 404 44.2 0.57 59.7 0.43 57.8 0.63
  1. LS least squares, MCS mental component summary, PCS physical component summary, SE standard error, SF-12v2 SF-12v2 Health Survey, SIBDQ Short Inflammatory Bowel Disease Questionnaire
  2. Findings for each outcome are based on mixed-effects models for repeated measures with subject as a random effect and visit as a fixed effect
  3. Week 8 includes early withdrawal visits during the acute phase. “Month 12” includes early withdrawal visits during the maintenance phase
  4. *P < 0.05, †P < 0.01, ‡P < 0.001